Pharmacogenetics of antidepressant drugs: current clinical practice and future directions (Q37989490)

26 August 2017

Pharmacogenetics of antidepressant drugs: current clinical practice and future directions (English)

1 reference

26 August 2017

Sneha Narasimhan

1

0 references

author name string

Falk W Lohoff

series ordinal

2

1 reference

26 August 2017

1 March 2012

1 reference

26 August 2017

1 reference

26 August 2017

13

1 reference

26 August 2017

4

1 reference

26 August 2017

441-464

1 reference

Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report

26 August 2017

1 reference

Predictors of drug response in depression

21 January 2018

1 reference

Metabolic Issues With Atypical Antipsychotics in Primary Care: Dispelling the Myths

21 January 2018

1 reference

National patterns in antidepressant medication treatment

21 January 2018

1 reference

Treatment of bipolar disorder: a complex treatment for a multi-faceted disorder

21 January 2018

1 reference

Generalized anxiety disorder: prevalence, burden, and cost to society.

21 January 2018

1 reference

Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication

21 January 2018

1 reference

Clinical applications of pharmacogenetics in psychiatry

21 January 2018

1 reference

Pharmacogenetics and pharmacogenomics: development, science, and translation

21 January 2018

1 reference

Cytochrome P4502D6 (CYP2D6) gene locus heterogeneity: characterization of gene duplication events.

21 January 2018

1 reference

Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs

21 January 2018

1 reference

Polymorphisms in the CYP 2D6 gene: association with plasma concentrations of fluoxetine and paroxetine

21 January 2018

1 reference

Venlafaxine serum levels and CYP2D6 genotype

21 January 2018

1 reference

CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine

21 January 2018

1 reference

Molecular genetics of the human cytochrome P450 monooxygenase superfamily

21 January 2018

1 reference

Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients.

21 January 2018

1 reference

Impact of CYP2C19 phenotypes on escitalopram metabolism and an evaluation of pupillometry as a serotonergic biomarker.

21 January 2018

1 reference

Effect of age, weight, and CYP2C19 genotype on escitalopram exposure

21 January 2018

1 reference

Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy

21 January 2018

1 reference

Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response.

21 January 2018

1 reference

Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder

21 January 2018

1 reference

Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting

21 January 2018

1 reference

Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample

21 January 2018

1 reference

Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression

21 January 2018

1 reference

Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption

21 January 2018

1 reference

Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-Glycoprotein gene disruption

21 January 2018

1 reference

Sertraline and its metabolite desmethylsertraline, but not bupropion or its three major metabolites, have high affinity for P-glycoprotein

21 January 2018

1 reference

The influence of P-glycoprotein on cerebral and hepatic concentrations of nortriptyline and its metabolites.

21 January 2018

1 reference

ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder.

21 January 2018

1 reference

Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response: a pilot study

21 January 2018

1 reference

ABCB1 (MDR1) polymorphisms and antidepressant response in geriatric depression

21 January 2018

1 reference

MDR1 gene polymorphism: therapeutic response to paroxetine among patients with major depression

21 January 2018

1 reference

Antidepressants and ABCB1 gene C3435T functional polymorphism: a naturalistic study.

21 January 2018

1 reference

Failure to replicate genetic associations with antidepressant treatment response in duloxetine-treated patients

21 January 2018

1 reference

Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTRK2: association with major depression and antidepressant response in Mexican-Americans

21 January 2018

1 reference

Differential tissue distribution of tryptophan hydroxylase isoforms 1 and 2 as revealed with monospecific antibodies.

21 January 2018

1 reference

Tryptophan hydroxylase gene associated with paroxetine antidepressant activity.

21 January 2018

1 reference

Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity.

21 January 2018

1 reference

Association between the tryptophan hydroxylase-1 gene A218C polymorphism and citalopram antidepressant response in a Korean population.

21 January 2018

1 reference

TPH1 218A/C polymorphism is associated with major depressive disorder and its treatment response

21 January 2018

1 reference

No association between the tryptophan hydroxylase gene polymorphism and major depressive disorders and antidepressant response in a Korean population

21 January 2018

1 reference

Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder.

21 January 2018

1 reference

No association of TPH1 218A/C polymorphism with treatment response and intolerance to SSRIs in Japanese patients with major depression.

21 January 2018

1 reference

Genetic predictors of response to antidepressants in the GENDEP project

21 January 2018

1 reference

Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder

21 January 2018

1 reference

Loss-of-function mutation in tryptophan hydroxylase-2 identified in unipolar major depression

21 January 2018

1 reference

Common genetic variations in human brain-specific tryptophan hydroxylase-2 and response to antidepressant treatment

21 January 2018

1 reference

Investigation of serotonin-related genes in antidepressant response

21 January 2018

1 reference

Tryptophan hydroxylase 2 gene is associated with major depression and antidepressant treatment response

21 January 2018

1 reference

A functional polymorphism in the monoamine oxidase A gene promoter

21 January 2018

1 reference

MAOA gene polymorphisms and response to mirtazapine in major depression.

21 January 2018

1 reference

Monoamine oxidase A variant influences antidepressant treatment response in female patients with Major Depression.

21 January 2018

1 reference

Association study of a monoamine oxidase a gene promoter polymorphism with major depressive disorder and antidepressant response

21 January 2018

1 reference

Pharmacogenetics of selective serotonin reuptake inhibitor response: a 6-month follow-up

21 January 2018

1 reference

Moclobemide response in depressed patients: association study with a functional polymorphism in the monoamine oxidase A promoter

21 January 2018

1 reference

Monoamine oxidase: A gene polymorphism, tryptophan hydroxylase gene polymorphism and antidepressant response to fluvoxamine in Japanese patients with major depressive disorder

21 January 2018

1 reference

Monoamine oxidase A gene polymorphism, 5-HT 2A receptor gene polymorphism and incidence of nausea induced by fluvoxamine

21 January 2018

1 reference

Monoamine oxidase a and catechol-o-methyltransferase functional polymorphisms and the placebo response in major depressive disorder

21 January 2018

1 reference

The MAOA T941G polymorphism and short-term treatment response to mirtazapine and paroxetine in major depression.

21 January 2018

1 reference

Variation in catechol-O-methyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder

21 January 2018

1 reference

Association of codon 108/158 catechol-O-methyltransferase gene polymorphism with the psychiatric manifestations of velo-cardio-facial syndrome

21 January 2018

1 reference

The catechol-O-methyltransferase Val(108/158)Met polymorphism affects antidepressant response to paroxetine in a naturalistic setting

21 January 2018

1 reference

Effect of catechol-O-methyltransferase Val(108/158)Met polymorphism on antidepressant efficacy of fluvoxamine.

21 January 2018

1 reference

The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression

21 January 2018

1 reference

Sexually dimorphic effect of catechol-O-methyltransferase val158met polymorphism on clinical response to fluoxetine in major depressive patients

21 January 2018

1 reference

Influence of the tyrosine hydroxylase val81met polymorphism and catechol-O-methyltransferase val158met polymorphism on the antidepressant effect of milnacipran

21 January 2018

1 reference

Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region

21 January 2018

1 reference

No evidence for in vivo regulation of midbrain serotonin transporter availability by serotonin transporter promoter gene polymorphism

21 January 2018

1 reference

No association between genotype of the promoter region of serotonin transporter gene and serotonin transporter binding in human brain measured by PET.

21 January 2018

1 reference

Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression

21 January 2018

1 reference

Age-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortriptyline

21 January 2018

1 reference

Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment

21 January 2018

1 reference

5-HTTLPR polymorphism of the serotonin transporter gene predicts non-remission in major depression patients treated with citalopram in a 12-weeks follow up study

21 January 2018

1 reference

The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder

21 January 2018

1 reference

Further evidence of a combined effect of SERTPR and TPH on SSRIs response in mood disorders

21 January 2018

1 reference

Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy

21 January 2018

1 reference

SLC6A4 variation and citalopram response

21 January 2018

1 reference

Moderation of antidepressant response by the serotonin transporter gene.

21 January 2018

1 reference

Serotonin transporter polymorphism (5-HTTLPR) and citalopram effectiveness and side effects in children with depression and/or anxiety disorders

21 January 2018

1 reference

Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression

21 January 2018

1 reference

Antidepressant response and the serotonin transporter gene-linked polymorphic region

21 January 2018

1 reference

Serotonin-2A-receptor and -transporter polymorphisms: lack of association in patients with major depression

21 January 2018

1 reference

A 40-basepair VNTR polymorphism in the dopamine transporter (DAT1) gene and the rapid response to antidepressant treatment.

21 January 2018

1 reference

Serotonin transporter gene polymorphisms and sertraline response in major depression patients

21 January 2018

1 reference

A variable number of tandem repeats in the serotonin transporter gene does not affect the antidepressant response to fluvoxamine

21 January 2018

1 reference

Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms.

21 January 2018

1 reference

Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients.

21 January 2018

1 reference

Interaction between serotonin transporter gene variants and life events predicts response to antidepressants in the GENDEP project.

21 January 2018

1 reference

Harm avoidance moderates the influence of serotonin transporter gene variants on treatment outcome in bipolar patients

21 January 2018

1 reference

Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression.

21 January 2018

1 reference

Evidence of a role for the 5-HTTLPR genotype in the modulation of motor response to antidepressant treatment

21 January 2018

1 reference

Serotonin transporter promoter region polymorphisms do not influence treatment response to escitalopram in patients with major depression

21 January 2018

1 reference

Serotonin transporter gene polymorphism associated with short-term treatment response to venlafaxine

21 January 2018

1 reference

Serotonin transporter polymorphism and bleeding time during SSRI therapy

21 January 2018

1 reference

Sequence analysis of the serotonin transporter and associations with antidepressant response

21 January 2018

1 reference

Serotonin transporter polymorphisms (SLC6A4 insertion/deletion and rs25531) do not affect the availability of 5-HTT to [11C] DASB binding in the living human brain.

21 January 2018

1 reference

Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: a systematic review.

21 January 2018

1 reference

Serotonin transporter polymorphisms and side effects in antidepressant therapy--a pilot study

21 January 2018

1 reference

Serotonin transporter polymorphisms and the occurrence of adverse events during treatment with selective serotonin reuptake inhibitors.

21 January 2018

1 reference

No association between the serotonergic polymorphisms and incidence of nausea induced by fluvoxamine treatment

21 January 2018

1 reference

Evidence for a combined genetic effect of the 5-HT(1A) receptor and serotonin transporter genes in the clinical outcome of major depressive patients treated with citalopram

21 January 2018

1 reference

Effect of 5-HT1A gene polymorphisms on antidepressant response in major depressive disorder.

21 January 2018

1 reference

Higher 5-HT1A receptor binding potential during a major depressive episode predicts poor treatment response: preliminary data from a naturalistic study

21 January 2018

1 reference

The C(-1019)G polymorphism of the 5-HT1A gene promoter and antidepressant response in mood disorders: preliminary findings

21 January 2018

1 reference

Association of the C(-1019)G 5-HT1A functional promoter polymorphism with antidepressant response

21 January 2018

1 reference

Serotonin receptor 1A-1019C/G variant: impact on antidepressant pharmacoresponse in melancholic depression?

21 January 2018

1 reference

Interaction of serotonin-related genes affects short-term antidepressant response in major depressive disorder

21 January 2018

1 reference

The effects of a 5-hydroxytryptamine 1A receptor gene polymorphism on the clinical response to fluvoxamine in depressed patients

21 January 2018

1 reference

Association study of two serotonin 1A receptor gene polymorphisms and fluoxetine treatment response in Chinese major depressive disorders

21 January 2018

1 reference

Serotonin receptor 2A gene polymorphism (-1438A/G) and short-term treatment response to citalopram

21 January 2018

1 reference

Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients.

21 January 2018

1 reference

HTR2A is associated with SSRI response in major depressive disorder in a Japanese cohort

21 January 2018

1 reference

Pharmacogenetics of antidepressant medication intolerance

21 January 2018

1 reference

Polymorphisms in the 5-hydroxytryptamine 2A receptor and CytochromeP4502D6 genes synergistically predict fluvoxamine-induced side effects in japanese depressed patients

21 January 2018

1 reference

A family based association study of T102C polymorphism in 5HT2A and schizophrenia plus identification of new polymorphisms in the promoter.

21 January 2018

1 reference

Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment

21 January 2018

1 reference

Resequencing of serotonin-related genes and association of tagging SNPs to citalopram response

21 January 2018

1 reference

Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment

21 January 2018

1 reference

HTR2A gene variation is involved in antidepressant treatment response

21 January 2018

1 reference

5HT1A and 5HT2A receptor genes in treatment response phenotypes in major depressive disorder.

21 January 2018

1 reference

Genetic polymorphisms in the 5-hydroxytryptamine type 3B receptor gene and paroxetine-induced nausea

21 January 2018

1 reference

Association between the 5-HT6 receptor C267T polymorphism and response to antidepressant treatment in major depressive disorder

21 January 2018

1 reference

Association study of the 5-HT(6) receptor polymorphism (C267T) and symptomatology and antidepressant response in major depressive disorders

21 January 2018

1 reference

On the effects of psychostimulants, antidepressants, and the antiparkinsonian drug levodopa on dopamine neurons.

21 January 2018

1 reference

The VNTR polymorphism of the human dopamine transporter (DAT1) gene affects gene expression

21 January 2018

1 reference

No association between dopamine D(2) and D(4) receptor gene variants and antidepressant activity of two selective serotonin reuptake inhibitors

21 January 2018

1 reference

Dopamine receptor D4 is not associated with antidepressant activity of sleep deprivation.

21 January 2018

1 reference

Number of risk genotypes is a risk factor for major depressive disorder: a case control study.

21 January 2018

1 reference

Norepinephrine and serotonin transporter genes: impact on treatment response in depression

21 January 2018

1 reference

Beta-1-adrenergic receptor gene in major depression: influence on antidepressant treatment response.

21 January 2018

1 reference

The corticosteroid receptor hypothesis of depression

21 January 2018

1 reference

Association study of corticotropin-releasing hormone receptor1 gene polymorphisms and antidepressant response in major depressive disorders.

21 January 2018

1 reference

Association of a corticotropin-releasing hormone receptor 1 haplotype and antidepressant treatment response in Mexican-Americans

21 January 2018

1 reference

Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment.

21 January 2018

1 reference

Prediction of treatment response by HPA-axis and glucocorticoid receptor polymorphisms in major depression.

21 January 2018

1 reference

Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment

21 January 2018

1 reference

The FKBP5-gene in depression and treatment response--an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort

21 January 2018

1 reference

Genetic variants in FKBP5 affecting response to antidepressant drug treatment.

21 January 2018

1 reference

Meta-analysis of FKBP5 gene polymorphisms association with treatment response in patients with mood disorders

21 January 2018

1 reference

Association of FKBP5 polymorphisms with suicidal events in the Treatment of Resistant Depression in Adolescents (TORDIA) study

21 January 2018

1 reference

Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder

21 January 2018

1 reference

Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression

21 January 2018

1 reference

Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort

21 January 2018

1 reference

Genetic markers of suicidal ideation emerging during citalopram treatment of major depression

21 January 2018

1 reference

Genetic and clinical predictors of sexual dysfunction in citalopram-treated depressed patients

21 January 2018

1 reference

Tianeptine increases brain-derived neurotrophic factor expression in the rat amygdala.

21 January 2018

1 reference

Chronic duloxetine treatment induces specific changes in the expression of BDNF transcripts and in the subcellular localization of the neurotrophin protein.

21 January 2018

1 reference

The effect of escitalopram, desipramine, electroconvulsive seizures and lithium on brain-derived neurotrophic factor mRNA and protein expression in the rat brain and the correlation to 5-HT and 5-HIAA levels

21 January 2018

1 reference

The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function

21 January 2018

1 reference

Brain-derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder.

21 January 2018

1 reference

The G196A polymorphism of the brain-derived neurotrophic factor gene and the antidepressant effect of milnacipran and fluvoxamine.

21 January 2018

1 reference

Brain derived neurotrophic factor gene polymorphism (Val66Met) and short-term antidepressant response in major depressive disorder

21 January 2018

1 reference

Association study of a brain‐derived neurotrophic‐factor genetic polymorphism and major depressive disorders, symptomatology, and antidepressant response

21 January 2018

1 reference

A splice site polymorphism in the G-protein beta subunit influences antidepressant efficacy in depression.

21 January 2018

1 reference

A brain-derived neurotrophic factor (BDNF) haplotype is associated with antidepressant treatment outcome in mood disorders.

21 January 2018

1 reference

Brain-derived neurotrophic factor ( BDNF) gene: no major impact on antidepressant treatment response

21 January 2018

1 reference

Novel sequence variations in the brain-derived neurotrophic factor gene and association with major depression and antidepressant treatment response

21 January 2018

1 reference

Genetic predictors of increase in suicidal ideation during antidepressant treatment in the GENDEP project.

21 January 2018

1 reference

Association of a human G-protein beta3 subunit variant with hypertension

21 January 2018

1 reference

SSRIs antidepressant activity is influenced by G beta 3 variants

21 January 2018

1 reference

Functional genomics approaches in arthritis

21 January 2018

1 reference

Variation in GNB3 predicts response and adverse reactions to antidepressants

21 January 2018

1 reference

Relationship between G-protein beta-3 subunit C825T polymorphism and mirtazapine responses in Korean patients with major depression

21 January 2018

1 reference

Antidepressant response and intolerance to SSRI is not influenced by G-protein beta3 subunit gene C825T polymorphism in Japanese major depressive patients.

21 January 2018

1 reference

Distinct mechanism for antidepressant activity by blockade of central substance P receptors

21 January 2018

1 reference

An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels

21 January 2018

1 reference

An insertion/deletion polymorphism in the angiotensin converting enzyme gene is associated with both brain substance P contents and affective disorders.

21 January 2018

1 reference

Genetic variants in the angiotensin I-converting-enzyme (ACE) and angiotensin II receptor (AT1) gene and clinical outcome in depression

21 January 2018

1 reference

Increased temporal cortex CREB concentrations and antidepressant treatment in major depression.

21 January 2018

1 reference

Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study.

21 January 2018

1 reference

A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression

21 January 2018

1 reference

Genome-wide pharmacogenetics of antidepressant response in the GENDEP project

21 January 2018

1 reference

A genomewide association study of citalopram response in major depressive disorder

21 January 2018

1 reference

What is the genetic relationship between anxiety and depression?

21 January 2018

1 reference

Pharmacogenetics of anxiolytic drugs.

21 January 2018

1 reference

Evidence for linkage disequilibrium between serotonin transporter protein gene (SLC6A4) and obsessive compulsive disorder.

21 January 2018

1 reference

Obsessive-Compulsive Disorder, 5-HTTLPR polymorphism and treatment response.

21 January 2018

1 reference

Antipanic efficacy of paroxetine and polymorphism within the promoter of the serotonin transporter gene

21 January 2018

1 reference

Tryptophan hydroxylase and serotonin transporter gene polymorphism does not affect the diagnosis, clinical features and treatment outcome of panic disorder in the Korean population

21 January 2018

1 reference

Serotonin transporter gene promoter polymorphism predicts SSRI response in generalized social anxiety disorder

21 January 2018

1 reference

Relation of serotonin transporter genetic variation to efficacy of escitalopram for generalized anxiety disorder in older adults

21 January 2018

1 reference

T102C and -1438 G/A polymorphisms of the 5-HT2A receptor gene in Turkish patients with obsessive-compulsive disorder.

21 January 2018

1 reference

D2 dopamine receptor gene polymorphism: paroxetine and social functioning in posttraumatic stress disorder

21 January 2018

1 reference

Cannabinoid receptor 1 (CNR1) gene: impact on antidepressant treatment response and emotion processing in major depression.

21 January 2018

1 reference

Association analysis between the Val66Met polymorphism in the brain-derived neurotrophic factor (BDNF) gene and treatment response to venlafaxine XR in generalized anxiety disorder

21 January 2018

1 reference

Signaling networks in the pathophysiology and treatment of mood disorders

21 January 2018

1 reference

Association analysis of a functional G protein beta3 subunit gene polymorphism (C825T) in mood disorders

21 January 2018

1 reference

Antidepressant-induced mania: an overview of current controversies

21 January 2018

1 reference

The role of serotonin transporter protein gene in antidepressant-induced mania in bipolar disorder: preliminary findings

21 January 2018

1 reference

Serotonin transporter linked promoter (polymorphism) in the serotonin transporter gene may be associated with antidepressant-induced mania in bipolar disorder

21 January 2018

1 reference

The role of 5-HTTLPR polymorphism in antidepressant-associated mania in bipolar disorder

21 January 2018

1 reference

Antidepressant-induced mania, rapid cycling and the serotonin transporter gene polymorphism

21 January 2018

1 reference

A pilot study of antidepressant-induced mania in pediatric bipolar disorder: Characteristics, risk factors, and the serotonin transporter gene

21 January 2018

1 reference

The pharmacogenetics of antidepressant-induced mania: a systematic review and meta-analysis

21 January 2018

1 reference

Brain-derived neurotrophic factor (BDNF) gene not associated with antidepressant-induced mania.

21 January 2018

1 reference

Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use.

21 January 2018

1 reference

Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients

21 January 2018

1 reference

Pharmacokinetics of venlafaxine extended release 75 mg and desvenlafaxine 50 mg in healthy CYP2D6 extensive and poor metabolizers: a randomized, open-label, two-period, parallel-group, crossover study

21 January 2018

1 reference

Efficacy of Paroxetine in Depression Is Influenced by a Functional Polymorphism Within the Promoter of the Serotonin Transporter Gene

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/PGS.12.1

1 reference

26 August 2017

1 reference

PubMed ID

22380000